Evidence map›Paper›PMID 40305656›Full record

ArticleACS chemical neuroscience2025

Monomers, Dimers, and Oligomers of Pyroglutamate-Modified α-Synuclein Fragments Exhibit Distinct Biophysical Characteristics.

Alexandra Bluhm, Wei Xiang, Frank Wien, Aurelien Thureau, Maelenn Chevreuil, Bertrand Raynal, Stefanie Geissler, Michael Wermann, Stephan Schilling, Philippe Bénas and 4 more

Abstract read
In one paragraph

Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alexandra BluhmPaul Flechsig Institute - Centre for Neuropathology and Brain Research, University of Leipzig, 04103 Leipzig, Germany.
Wei XiangUniversity Hospital Erlangen, Department Molecular Neurology, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany.
Frank WienSynchrotron SOLEIL, L'Orme des Merisiers Saint Aubin, 91410 Gif-sur-Yvette, France.ORCID 0000-0002-0752-8735
Aurelien ThureauSynchrotron SOLEIL, L'Orme des Merisiers Saint Aubin, 91410 Gif-sur-Yvette, France.
Maelenn ChevreuilPlateforme de biophysique moléculaire, C2RT, Institut Pasteur, Université Paris Cité, 75015 Paris, France.
Bertrand RaynalPlateforme de biophysique moléculaire, C2RT, Institut Pasteur, Université Paris Cité, 75015 Paris, France.
Stefanie GeisslerFraunhofer Institute for Cell Therapy and Immunology, Department of Molecular Drug Design and Target Validation, 06120 Halle (Saale), Germany.
Michael WermannFraunhofer Institute for Cell Therapy and Immunology, Department of Molecular Drug Design and Target Validation, 06120 Halle (Saale), Germany.
Stephan SchillingFraunhofer Institute for Cell Therapy and Immunology, Department of Molecular Drug Design and Target Validation, 06120 Halle (Saale), Germany.
Philippe BénasCNRS, Architecture et Réactivité de l'ARN, UPR 9002, Institut de Biologie Moléculaire et Cellulaire, Université de Strasbourg, 67084 Strasbourg, France.
Maike Hartlage-RübsamenPaul Flechsig Institute - Centre for Neuropathology and Brain Research, University of Leipzig, 04103 Leipzig, Germany.
Anja SchulzeFraunhofer Institute for Cell Therapy and Immunology, Department of Molecular Drug Design and Target Validation, 06120 Halle (Saale), Germany.
Claude SauterCNRS, Architecture et Réactivité de l'ARN, UPR 9002, Institut de Biologie Moléculaire et Cellulaire, Université de Strasbourg, 67084 Strasbourg, France.
Steffen RoßnerPaul Flechsig Institute - Centre for Neuropathology and Brain Research, University of Leipzig, 04103 Leipzig, Germany.ORCID 0000-0002-9959-283X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

α-Synuclein (aSyn) aggregation represents a key event in the neurodegenerative cascade of synucleinopathies. Initially, aSyn appears as an intrinsically disordered protein. However, its structural flexibility allows aSyn to either adopt α-helical conformations, relevant for physiological functions at presynaptic vesicles, or form β-strand-rich aggregates, leading to toxic oligomers. This relation between structure, function, and toxicity can be influenced by post-translational modifications such as the recently identified glutaminyl cyclase-catalyzed pyroglutamate (pE) modification. Here, we investigated (i) structural characteristics of monomeric, dimeric, and oligomeric states of N-terminal truncated, pE-modified aSyn variants, pE24-, pE62-, and pE79-aSyn by a complementary biophysical approach including DLS, SEC-MALS, SRCD, SEC-SAXS, and AUC and (ii) the toxicity of oligomeric pE-aSyn variants compared to full-length aSyn. Overall, pE62-aSyn showed an immediate fibril formation, reflecting the aggregation-prone properties of this particular variant. Furthermore, in a membrane-like environment, the secondary aSyn structure shifted toward α-helical folding depending on the degree of N-terminal truncation. pE79-aSyn showed a significantly reduced level of structural adaptation, reflecting compromised functions at presynaptic vesicles. In addition, the comparative analysis indicates the presence of a dimeric aSyn intermediate, the initial and potentially crucial step in aSyn aggregation, and supports the hypothesis of a toxic porous oligomeric state. For the first time, based on SAXS data, EOM models of the dimeric aSyn state are proposed.

Indexed as

alpha-SynucleinPyrrolidonecarboxylic AcidHumansProtein MultimerizationProtein Processing, Post-Translationalalpha-SynucleinPyrrolidonecarboxylic Acidbiophysical characterizationEOM modelingN-terminal truncationpyroglutamate modificationα-synuclein

Identifiers

PMID40305656
PMCPMC12100652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.